Research and experimental development on natural sciences and engineering
SERCA PHARMACEUTICALS AS
Revenue 2024
NOK 4.7m
Operating profit
NOK −1.5m
Equity
NOK 27.6m
Incorporated
2018
Share capital
NOK 896,000
Key figures · 2024
Current ratio
3.07
Equity ratio
68.1%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -32.4% | |
| Net margin (%%) | -24.6% | |
| Return on assets (%%) | -3.8% | |
| Likviditet | ||
| Current ratio | 3.07 | |
| Working capital | 9.0m | |
| Soliditet | ||
| Equity ratio (%%) | 68.1% | |
| Debt-to-equity ratio | 0.47 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.